Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Details 詳細情報について

• CRID

  1360298760872554112

• DOI

  10.1016/s1470-2045(19)30504-2

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204519305042?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204519305042?httpAccept=text/plain

• Data Source

  • Crossref